Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 406Carcinoma, Non-Small-Cell Lung 147Urinary Bladder Neoplasms 87Breast Neoplasms 84Cholangiocarcinoma 82Lung Neoplasms 78Neoplasm Metastasis 67Neoplasms 64Biliary Tract Neoplasms 58Nasopharyngeal Carcinoma 53Ovarian Neoplasms 46Sarcoma 43Recurrence 39Gallbladder Neoplasms 39Hodgkin Disease 34Lymphoma, Large B-Cell, Diffuse 33Lymphoma 32Carcinoma, Transitional Cell 29Bile Duct Neoplasms 24Adenocarcinoma 23Fallopian Tube Neoplasms 19Carcinoma, Hepatocellular 19Adenocarcinoma of Lung 18Triple Negative Breast Neoplasms 17Lymphoma, Non-Hodgkin 17Liver Neoplasms 17Nasopharyngeal Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Carcinoma 16Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Gemcitabine 2selicrelumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma Pancreas × Gemcitabine × Clear all
NCT02812992 2021-08-10

GrantPax

AIO-Studien-gGmbH

Phase 4 Completed
32 enrolled
Gastrointestinal

Adenocarcinoma Pancreas

NCT01456585 2018-08-27

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
10 enrolled
Gastrointestinal

Adenocarcinoma Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡